Home » Business » Manufacturing
Genzyme rejects Sanofi's bid again
Source: Agencies |
August 31, 2010, Tuesday
|
Print Edition
Print Edition
GENZYME Corp rejected a US$18.5 billion takeover offer from French drug maker Sanofi-Aventis, saying it dramatically undervalues the company.
The Cambridge, Massachusetts-based biotechnology company said its board of directors met late Sunday and unanimously affirmed a previous rejection of Sanofi's proposal.
In a letter to Sanofi's chief executive, Chris Viehbacher, Genzyme said the French firm's proposal to acquire Genzyme for US$69 a share is the same as an offer it made last month.
"It provides no new information and no improvement in price, and therefore fails to establish a basis for engagement by the Genzyme board," Genzyme said.
Genzyme said that in its first response letter to Sanofi, dated July 29, the board said it was not the right time to sell the company "because your opportunistic takeover proposal does not begin to recognize the significant progress underway to rectify our manufacturing challenges or the potential for our new-product pipeline."
Genzyme said in its latest letter to Sanofi, "Our board met last evening in response to your second letter and unanimously confirmed those views."
The Cambridge, Massachusetts-based biotechnology company said its board of directors met late Sunday and unanimously affirmed a previous rejection of Sanofi's proposal.
In a letter to Sanofi's chief executive, Chris Viehbacher, Genzyme said the French firm's proposal to acquire Genzyme for US$69 a share is the same as an offer it made last month.
"It provides no new information and no improvement in price, and therefore fails to establish a basis for engagement by the Genzyme board," Genzyme said.
Genzyme said that in its first response letter to Sanofi, dated July 29, the board said it was not the right time to sell the company "because your opportunistic takeover proposal does not begin to recognize the significant progress underway to rectify our manufacturing challenges or the potential for our new-product pipeline."
Genzyme said in its latest letter to Sanofi, "Our board met last evening in response to your second letter and unanimously confirmed those views."
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
